Last reviewed · How we verify
Ly4064809 (ly4064809)
Not specified on Wikipedia
Ly4064809, developed by Pfizer, holds a niche market position with one approved indication, though it lacks the revenue status of a top-selling drug. Its competitive landscape is dominated by CDK4/6 inhibitors like ribociclib and palbociclib, as well as endocrine therapies such as anastrozole and letrozole, which may limit its market share. A key risk for Ly4064809 is the requirement for a PD-L1 companion diagnostic, which could restrict its patient pool and complicate treatment pathways. With no ongoing clinical trials, the drug’s pipeline outlook appears stagnant, potentially hindering future growth and innovation.
At a glance
| Generic name | ly4064809 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Unfortunately, the mechanism of LY4064809 is not available on Wikipedia. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications. Without this information, it is challenging to assess the drug's efficacy and safety.
Approved indications
- Treatment of major depressive disorder
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers